Why Juno Therapeutics Stock Fell Last Week
Juno Therapeutics (NASDAQ: JUNO) reported some pretty good data at last week's American Society of Hematology conference, but the stock bombed shortly after.
In this clip from Industry Focus: Healthcare, analyst Kristine Harjes and contributor Todd Campbell explain why, and whether or not investors might want to see this as a buying opportunity. Find out how Juno's non-Hodgkin lymphoma drug is different form the current standard of care, and why it's so exciting for patients; what about the relatively good data has investors so nervous; why performing these trials is getting more and more expensive and difficult; why investors don't want to count Juno out just yet; and more.
A full transcript follows the video.
Source: Fool.com
